The FDA recently approved a new drug RelyvrioTM (a coformulation of sodium phenylbutyrate and taurursodiol; previously known as AMX0035) for the treatment of amyotrophic lateral sclerosis (ALS). This is the third FDA-approved medication in treating patients with ALS after riluzole (Rilutek) in 1995 and edaravone (Radicava) in 2017 (Table 1) from more than 80 randomized controlled clinical trials for ALS therapies.

PDF (Download Full text)